Severe Community-Acquired Pneumonia (CAP) Admission Order Set: ICU Triage, Antibiotics, Adjuncts, and Day-by-Day Workflow

Order Set · Pulmonary / Critical Care

Severe Community-Acquired Pneumonia (CAP) Admission Order Set: ICU Triage, Antibiotics, Adjuncts, and Day-by-Day Workflow

📅 Updated September 5 ⏱ 18 min read 👤 gomdori, MD

Overview

Severe community-acquired pneumonia (CAP) is the form requiring intensive care admission and frequently mechanical ventilation, vasopressor support, or both. The IDSA/ATS 2019 definition uses 9 minor criteria (≥3 of which qualify for ICU) plus 2 major criteria (either alone qualifies): septic shock requiring vasopressors and respiratory failure requiring mechanical ventilation. Mortality in severe CAP remains substantial (15–30%) and is highly time-dependent — every hour of delay in appropriate antibiotic therapy worsens outcomes.

This order set captures the first-hour, first-day, and through-discharge interventions: triage scoring (PSI/CURB-65), empirical antibiotic selection by MRSA/Pseudomonas risk profile, adjunctive corticosteroids in selected severe cases (CAPE-COD trial), conservative fluid strategy, mechanical ventilation parameters (lung-protective tidal volume), VTE and stress ulcer prophylaxis, daily de-escalation rounds, and discharge criteria. It is designed for use by hospitalists, intensivists, and emergency physicians admitting adult CAP patients to the ICU or step-down unit.

15–30%
Severe CAP mortality
≤4 h
First antibiotic dose
≥3 / 9
Minor IDSA criteria
200 mg/d
Hydrocortisone (CAPE-COD)

1. Severity Triage and ICU Admission

IDSA/ATS 2019 ICU admission criteria — both major and minor: ICU admission is required for any patient meeting ONE major criterion (mechanical ventilation OR septic shock requiring vasopressors) OR meeting at least THREE of nine minor criteria. The minor criteria are: respiratory rate ≥30/min, PaO2/FiO2 ≤250, multilobar infiltrates, confusion/disorientation, uremia (BUN ≥20 mg/dL), leukopenia (WBC <4,000), thrombocytopenia (platelets <100,000), hypothermia (core temperature <36°C), and hypotension requiring aggressive fluid resuscitation. SMART-COP and ATS criteria perform similarly to CURB-65 for triage but include lactate and pH which add prognostic discrimination in early sepsis. The single most useful bedside add-on in practice is point-of-care lactate; lactate ≥4 mmol/L in a CAP patient who looks "borderline" by minor criteria alone should escalate triage toward ICU regardless of the formal count. The dominant triage error in community hospital practice is admitting "borderline severe" CAP to floor beds and finding them on the rapid response cart 12-24 hours later — the threshold for ICU should be lower, not higher.

IDSA/ATS 2019 minor and major criteria

ICU admission is mandated when ≥1 major criterion or ≥3 minor criteria are met:

TypeCriterion
Major (any one → ICU)Septic shock requiring vasopressors
Major (any one → ICU)Respiratory failure requiring mechanical ventilation
Minor (≥3 → ICU)Respiratory rate ≥30/min
MinorPaO2/FiO2 ≤250
MinorMultilobar infiltrates
MinorConfusion / disorientation
MinorUremia (BUN ≥20 mg/dL)
MinorLeukopenia (WBC <4,000/μL)
MinorThrombocytopenia (platelets <100,000/μL)
MinorHypothermia (core T <36°C)
MinorHypotension requiring aggressive fluid resuscitation

PSI vs CURB-65

PSI (Pneumonia Severity Index) classes IV–V and CURB-65 ≥2 identify candidates for hospital admission, but neither replaces the IDSA/ATS criteria for ICU triage. Use CURB-65 (Confusion, Urea >7 mmol/L or BUN >19 mg/dL, Respiratory rate ≥30, Blood pressure SBP <90 or DBP ≤60, age ≥65) as a quick bedside score — 0–1 outpatient candidate, 2 admit to ward, 3–5 consider ICU. PSI is more granular but slower to calculate and better for risk stratification within a study population than at the bedside.

Always Apply Clinical Judgment Above Scores

A young patient with PSI class II but a respiratory rate of 38, multilobar consolidation, and a falling SpO2 needs ICU admission regardless of score. Conversely, a frail older patient with PSI class V and dementia in a stable state may be best managed on the ward with goals-of-care discussions. Scores guide; clinical judgment decides.

2. Initial Workup Orders (First Hour)

Time-zero is hospital arrival or ICU transfer. The first-hour bundle for severe CAP mirrors the sepsis bundle when sepsis criteria are met:

OrderSpecifics
Vital signsHR, BP, RR, SpO2 q15min × 4 then q1h; continuous telemetry; core temp q4h
IV accessTwo large-bore peripheral IVs; arterial line if vasopressor or PaO2 needed; central line if multiple infusions
Labs (within 30 min)CBC with differential, BMP/CMP, magnesium, phosphate, lactate, procalcitonin (baseline), troponin, BNP if HF suspected, ABG, coagulation panel
Microbiology (before antibiotics if no delay)Two sets of blood cultures from different sites; sputum Gram stain and culture; urinary Streptococcus pneumoniae and Legionella antigens; respiratory viral panel (PCR — influenza, RSV, COVID-19); pleural fluid analysis if effusion ≥1 cm on lateral decubitus
ImagingChest X-ray (PA/lateral if possible); chest CT if cavitation, complication, or diagnostic uncertainty; bedside lung ultrasound for effusion/consolidation
OxygenTitrate to SpO2 92–96% (88–92% for COPD); start nasal cannula 2–4 L/min; escalate to high-flow nasal cannula 30–60 L/min FiO2 0.4–1.0; non-invasive ventilation if hypercapnic; intubation if persistent hypoxemia, hemodynamic compromise, or progressive failure
IV fluidIf sepsis/septic shock: crystalloid 30 mL/kg IV over 3 hours, then conservative strategy; preferred fluid: balanced crystalloid (LR or Plasma-Lyte over 0.9% NaCl)
AntibioticsWithin 1 hour for septic shock; within 4 hours regardless — see Section 3 for empirical regimens
Vasopressor (if shock persists after fluids)Norepinephrine 0.05 mcg/kg/min IV titrated to MAP ≥65 mmHg; target central line if continuing >6 hours
OtherFoley catheter for hourly UO; NG tube if intubated; head-of-bed ≥30° if intubated (VAP prophylaxis); chlorhexidine oral care

Pearl — Don't delay antibiotics for cultures

If blood cultures cannot be drawn within 30–45 minutes of arrival in a septic-shock patient, give antibiotics first. The mortality benefit of timely antibiotic administration substantially outweighs the diagnostic yield benefit of pre-antibiotic cultures, particularly because empirical regimens are broad enough to cover the likely pathogens.

Pitfall — Excessive crystalloid in CAP

Once initial 30 mL/kg resuscitation is complete and MAP is restored, switch to a conservative fluid strategy. Excess crystalloid in CAP worsens hypoxemia, prolongs ventilation, and increases mortality (FACTT trial in ARDS data extrapolated). Use dynamic measures (passive leg raise, pulse pressure variation) to assess fluid responsiveness rather than chasing CVP targets.

3. Empirical Antibiotic Selection

Standard severe CAP regimen

The IDSA/ATS 2019 standard for severe CAP without MRSA or Pseudomonas risk:

  • Beta-lactam: Ceftriaxone 1–2 g IV q24h OR cefotaxime 1–2 g IV q8h OR ampicillin-sulbactam 3 g IV q6h
  • PLUS Atypical coverage (one of):
    • Azithromycin 500 mg IV q24h (preferred — better tolerated)
    • Doxycycline 100 mg IV/PO q12h (macrolide alternative)
    • Respiratory fluoroquinolone monotherapy (replaces both beta-lactam + macrolide):
      • Levofloxacin 750 mg IV q24h OR
      • Moxifloxacin 400 mg IV q24h

Atypical coverage is mandatory in severe CAP because Legionella, Mycoplasma, and Chlamydia carry significant mortality without targeted therapy. Macrolides may add anti-inflammatory benefit beyond antimicrobial activity in severe CAP. Avoid empirical fluoroquinolone monotherapy in TB-prevalent regions or in patients at risk of TB because partial fluoroquinolone treatment may obscure subsequent TB diagnosis.

MRSA / Pseudomonas coverage

Add MRSA or Pseudomonas coverage only when locally validated risk factors are present; routine empirical addition without risk factors increases adverse events without improving outcomes (per IDSA 2019 guideline change from 2007).

PathogenRisk factors warranting empirical coverageEmpirical agents
MRSAPrior MRSA isolation (especially respiratory); recent IV antibiotics in 90 days; hospitalization in 90 days; gram-positive cocci in clusters on Gram stain; cavitary necrotizing pneumonia; post-influenza pneumoniaVancomycin 25–30 mg/kg IV loading then AUC-targeted (AUC 400–600 mg·h/L) OR linezolid 600 mg IV q12h
Pseudomonas aeruginosaPrior Pseudomonas isolation; structural lung disease (bronchiectasis, advanced COPD); recent IV antibiotics; immunocompromise; gram-negative bacilli on Gram stainReplace ceftriaxone with antipseudomonal agent: piperacillin-tazobactam 4.5 g IV q8h (extended infusion) OR cefepime 2 g IV q8h OR meropenem 1 g IV q8h — keep macrolide/doxycycline for atypical

De-escalation occurs by day 2–3 once cultures and procalcitonin trends are available. If MRSA nasal swab PCR is negative and no MRSA grows from sputum/blood by 48 hours, vancomycin can usually be stopped. If sputum and blood cultures grow only susceptible Streptococcus pneumoniae, narrow to ampicillin or penicillin G monotherapy.

Procalcitonin Guides Antibiotic Duration, Not Initiation

Initiate empirical antibiotics for severe CAP based on clinical syndrome, not procalcitonin (which can be normal in early bacterial pneumonia). Use procalcitonin trends to support de-escalation and discontinuation decisions: a downward trend with clinical improvement supports stopping antibiotics earlier, often at 5–7 days rather than the historical 10–14. A persistently elevated procalcitonin should prompt reassessment for treatment failure or alternative diagnoses.

4. Adjunctive Therapy and Supportive Care

Hydrocortisone (CAPE-COD)

The CAPE-COD trial established that adjunctive hydrocortisone reduces 28-day mortality in severe CAP from 11.9% to 6.2% (NNT ~17) when given to patients meeting any of: PaO2/FiO2 <300 with FiO2 ≥0.5 on mechanical ventilation, non-invasive ventilation/HFNC with PaO2/FiO2 <300, PSI score >130, or radiographic multilobar involvement. Exclusions include septic shock at randomization and influenza-confirmed pneumonia.

  • Regimen: Hydrocortisone 200 mg IV continuous infusion daily × 4–7 days, then taper over 4–6 days based on clinical course (200 → 100 → 50 mg per day).
  • Start within 24 hours of severe CAP recognition; benefit not seen with delayed initiation.
  • Glucose control — Steroid-induced hyperglycemia common; target 140–180 mg/dL with insulin infusion. Monitor q4–6h initially.
  • Avoid in: confirmed influenza pneumonia (potential harm), aspergillosis, varicella, suspected bacterial endocarditis without source control, recent live vaccine.

Mechanical ventilation strategy

For intubated severe CAP patients, apply lung-protective ventilation (ARDSnet principles) regardless of formal ARDS criteria:

ParameterTarget / Setting
Tidal volume6 mL/kg predicted body weight (range 4–8 mL/kg)
Plateau pressure≤30 cm H2O
Driving pressure≤15 cm H2O (Pplat − PEEP)
PEEPLower PEEP/higher FiO2 table for CAP without ARDS; higher PEEP table if PaO2/FiO2 <200
FiO2 / SpO2 targetSpO2 92–96%; lowest FiO2 to maintain
Respiratory rateTitrate to pH ≥7.25; permissive hypercapnia acceptable (PaCO2 50–80, pH ≥7.20)
Prone positioningIf PaO2/FiO2 <150 despite 12 hours optimization → 16-h prone sessions per PROSEVA
SedationTargeted RASS −2 to 0; daily SAT/SBT; analgosedation preferred (fentanyl-based)

Other supportive care: VTE prophylaxis with enoxaparin 40 mg SC daily (CrCl ≥30) or unfractionated heparin 5000 units SC q8h (CrCl <30) — start within 24 h unless active bleeding. Stress ulcer prophylaxis with pantoprazole 40 mg IV daily for ventilated or coagulopathic patients. Glucose control 140–180 mg/dL. Nutrition — enteral feeding within 24–48 h via NG/OG tube once hemodynamically stable, target 25–30 kcal/kg/day.

Recognize Treatment Failure Early

Failure of clinical improvement by 48–72 hours of appropriate empirical therapy demands urgent re-evaluation. Differential includes: drug-resistant pathogen (MDR bacteria, NTM, fungal), wrong diagnosis (PE, vasculitis, pulmonary edema, drug-induced lung disease, malignancy), complications (empyema, lung abscess, ARDS), inadequate dosing (especially in obesity), or co-infection (viral plus bacterial, secondary bacterial post-influenza). Repeat imaging (CT chest), bronchoscopy with BAL, and infectious diseases consultation.

5. Day-by-Day Workflow and De-escalation

DayClinical assessmentLab / micro / imagingAntibiotic action
Day 0 (admission)Triage, ABCs, sepsis bundle, oxygen, intubation if neededCBC, BMP, lactate, ABG, blood + sputum cultures, urinary antigens, viral PCR, CXR ± CTEmpirical regimen within 4 hours (1 hour if shock)
Day 1Reassess shock, oxygenation, fluid status; consider hydrocortisoneDaily CBC, BMP, procalcitonin; recheck lactate if elevatedContinue empirical; review urinary antigens (Strep pneumo, Legionella) if rapid result
Day 2Reassess clinical improvement; SAT/SBT if ventedSputum culture results often available; blood cultures if positive (preliminary)De-escalate vancomycin if MRSA nasal PCR negative + no MRSA on cultures; consider narrowing if pathogen identified
Day 3Reassess for treatment failure if no improvement; lung ultrasound for effusion progressionFinal culture sensitivities; procalcitonin trendNarrow to pathogen-directed therapy; stop atypical coverage if not needed; switch IV→PO if eating, hemodynamically stable, afebrile ≥24h
Day 4–5Mobilize, wean ventilation, reduce vasopressorsWeekly CBC; LFTs at days 5–7 (especially with linezolid, vancomycin)Total duration typically 5–7 days for uncomplicated severe CAP if afebrile + stable; longer (10–14 days) for Pseudomonas, MRSA, S. aureus, Legionella, complicated effusion, lung abscess, immunocompromise
Day 6+Step down from ICU when stable; pulmonary rehab planningDischarge labsComplete antibiotic course; ensure oral regimen if discharged before completion

De-escalation is not optional — it reduces C. difficile, MDR organism selection, and adverse drug events. Document the rationale for any prolonged broad-spectrum coverage in the chart. Daily antimicrobial stewardship rounds in ICUs improve de-escalation rates and shorten duration without increasing failure.

6. Discharge Criteria and Outpatient Transition

Discharge from the ICU and from hospital follows graduated criteria:

ICU → Step-down or Ward (criteria)

  • Off vasopressors ≥6–12 hours; MAP ≥65 mmHg without support
  • SpO2 ≥92% on FiO2 ≤0.4 (or appropriate baseline for chronic respiratory disease)
  • Extubated and tolerating; or stable on chronic ventilator settings (e.g., trach)
  • Hemodynamically stable; HR <120; resolving lactic acidosis
  • No new organ dysfunction in past 24 hours

Hospital discharge (criteria)

  • Afebrile ≥24 hours (some guidelines: 48 hours)
  • Vital signs stable: HR <100, RR <24, SBP >90, SpO2 ≥90% on room air or chronic baseline FiO2
  • Tolerating oral intake and oral antibiotics
  • Mental status at baseline
  • Reliable home support and follow-up arranged
  • Clear understanding of red-flag symptoms (worsening dyspnea, fever, chest pain) and how to seek care

Discharge Orders

  • Antibiotic completion — Switch IV to PO once tolerating oral; common transitions: ceftriaxone+azithromycin → amoxicillin-clavulanate 875 mg PO BID + azithromycin 500 mg PO daily, or levofloxacin IV→PO 750 mg daily. Total course 5–7 days uncomplicated; 10–14 days for Pseudomonas/MRSA/Legionella/complicated.
  • Pneumococcal vaccination — PCV20 or PCV15+PPSV23 prior to or at discharge if not already received per ACIP age and risk recommendations.
  • Influenza vaccination — In season, prior to discharge.
  • Smoking cessation counseling and pharmacotherapy if active smoker.
  • Pulmonary rehab referral for any patient with pre-existing chronic lung disease or prolonged ICU stay.
  • Outpatient follow-up — Primary care within 7 days; chest imaging at 6 weeks if persistent symptoms or risk factors for malignancy (smoker over 50, abnormal initial imaging beyond consolidation, persistent radiographic abnormality).

When to Call Pulmonology / ID

Pulmonology: persistent radiographic abnormality at 6 weeks despite clinical recovery, suspected malignancy, suspected interstitial lung disease, recurrent CAP in same lobe (obstructive lesion), or chronic bronchiectasis. Infectious Diseases: treatment failure at 48–72h despite appropriate empirical therapy, MDR organism isolated, suspected NTM or fungal pneumonia, immunocompromised host with severe CAP, suspected hospital-acquired/ventilator-associated complication.

Frequently Asked Questions

When should the first antibiotic dose be given for severe CAP?
Within 1 hour of recognition for septic shock and within 4 hours of hospital arrival for severe CAP without shock. Each hour of delay in appropriate antibiotic administration is associated with worse outcomes. If blood cultures cannot be drawn quickly, give antibiotics first — the diagnostic yield benefit of pre-antibiotic cultures is outweighed by the mortality benefit of timely treatment.
Should every severe CAP patient receive hydrocortisone?
No. The CAPE-COD criteria are: severe CAP requiring ICU admission with PaO2/FiO2 less than 300 on mechanical ventilation/NIV/HFNC at FiO2 of 0.5 or greater, PSI greater than 130, or multilobar radiographic involvement. Hydrocortisone 200 mg/day IV continuous infusion for 4 to 7 days reduced 28-day mortality from 11.9 to 6.2 percent in this trial. Exclude patients with confirmed influenza pneumonia, aspergillosis, varicella, or other contraindications. Hydrocortisone should be started within 24 hours of recognition.
When should empirical MRSA and Pseudomonas coverage be added?
Add MRSA coverage (vancomycin or linezolid) only when validated risk factors are present — prior MRSA isolation, recent IV antibiotics, recent hospitalization, gram-positive cocci in clusters on Gram stain, cavitary necrotizing pneumonia, or post-influenza pneumonia. Add Pseudomonas coverage (replace ceftriaxone with piperacillin-tazobactam, cefepime, or meropenem) for prior Pseudomonas isolation, structural lung disease, immunocompromise, or gram-negative bacilli on Gram stain. Routine empirical addition of these without risk factors increases adverse events and selects MDR pathogens without improving outcomes.
How long should antibiotic therapy continue?
For uncomplicated severe CAP with clinical improvement and afebrile status by day 3, total duration of 5–7 days is generally sufficient. Procalcitonin trends can guide individual duration. Longer courses (10–14 days) are appropriate for Pseudomonas, MRSA, S. aureus, Legionella, complicated parapneumonic effusion, lung abscess, or immunocompromise. Always switch from IV to oral once the patient is hemodynamically stable, afebrile for 24 hours, tolerating PO, and improving clinically.
What is the role of urinary antigen testing in severe CAP?
Urinary Streptococcus pneumoniae and Legionella antigen tests are recommended in severe CAP because they yield rapid (<1 hour) results that can guide de-escalation. Positive Strep pneumoniae antigen supports narrowing to penicillin or amoxicillin if susceptible. Positive Legionella antigen confirms Legionella pneumophila serogroup 1 (the most common cause) and informs duration (typically 14–21 days for severe Legionella) and source investigation. Negative tests do not exclude these pathogens but a negative urinary Legionella antigen reduces probability substantially.

S7. the established Protocol Experience: Severe CAP from Admission to De-escalation

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Severe community-acquired pneumonia often walks into triage on its own legs and declares itself an hour later in the resuscitation bay, and mortality differentials in this population trace to four specific operational points: triage decisions made in the first hour of arrival (floor vs ICU), antibiotic timing relative to blood cultures, recognition of the need for MRSA and Pseudomonas coverage in specific risk profiles, and the post-2023 incorporation of hydrocortisone into severe CAP without shock. Experienced practice now moves borderline-severe patients toward ICU earlier, hard-stop the antibiotic clock at 1 hour from triage with cultures drawn within that window, and applies CAPE COD-style hydrocortisone explicitly to severe CAP requiring high-flow oxygen or NIV.

1. Lactate Triages the Borderline Patient

In practice, every CAP patient who meets 2 of 9 IDSA minor criteria (or 1 minor + clinician concern) gets a point-of-care lactate within 15 minutes of triage. Lactate ≥4 mmol/L in this borderline group pushes triage toward ICU regardless of the formal minor count. Experience has shown too many patients with 2 minors + lactate 5.2 stay on the floor for 18 hours before crashing. Conversely, lactate <2 mmol/L with 3 minors but otherwise stable physiology can often be observed on a step-down unit with q1-hour reassessment. Combining the formal criteria with lactate has substantially better discrimination than either alone in experienced hands.

2. Hour-1 Antibiotic with Cultures Drawn First

The IDSA/ATS recommendation is antibiotics within the first hour of severe CAP recognition, AND blood cultures drawn before antibiotic when feasible without delaying the antibiotic. In practice, the ED triage process draws blood cultures from a peripheral site at the same time as the initial IV access — there is essentially zero delay if the team is organized. Experienced practice does NOT accept the "we will get cultures after antibiotic" pathway because culture sensitivity drops substantially within 30 minutes of antibiotic, and identification of the causative organism drives downstream de-escalation. Experienced practice writes standing orders: blood cultures × 2 from separate sites + first antibiotic dose, both within 60 minutes of severe CAP triage call.

3. MRSA and Pseudomonas Risk-Stratified

Empirical coverage for severe CAP in the unit is: ceftriaxone 2 g IV daily + azithromycin 500 mg IV daily for typical severe CAP without risk factors. Experienced practice adds MRSA coverage (vancomycin or linezolid) when ANY of: recent prior MRSA respiratory isolate, cavitary infiltrate on imaging, post-influenza CAP, ESRD on hemodialysis, recent hospitalization or IV antibiotic within 90 days. Experienced practice adds Pseudomonas coverage (substitute piperacillin-tazobactam or cefepime for ceftriaxone) for: structural lung disease (bronchiectasis, advanced COPD on home oxygen, CF), recent hospitalization or IV antibiotic within 90 days, prior Pseudomonas respiratory isolate. The risk-stratified approach avoids both undertreatment and the empirical "everyone gets vanc-cefepime" overuse pattern.

4. Hydrocortisone Post-CAPE COD

The 2023 CAPE COD trial demonstrated mortality benefit for hydrocortisone 200 mg IV daily continuous infusion (or 50 mg IV q6h) for 4 days then taper, in severe CAP requiring high-flow nasal cannula, NIV, or mechanical ventilation. Routinely, experienced practice now incorporates this into severe CAP admission orders when respiratory support meets the trial threshold AND the patient is NOT in septic shock requiring vasopressors (which already has separate corticosteroid evidence — Hydrocortisone Plus Fludrocortisone for Adults with Septic Shock / APROCCHSS protocol). The two evidence bases do not perfectly overlap, but in patients in shock from severe CAP, the steroid is going on either way. Experienced clinicians exclude active fungal pneumonia, untreated TB, and influenza pneumonia (where steroid risk-benefit is murkier).

Illustrative Scenario: Borderline Severe CAP Saved by Lactate

A late-50s man presented to a community hospital ED with cough, fever 38.6°C, productive sputum, and dyspnea for 3 days. Vitals on arrival: RR 28, SpO2 91% on room air, BP 108/62, HR 112, GCS 15. CXR showed bilateral lower lobe infiltrates. Initial CURB-65 was 1 (RR not yet ≥30), and he met only 2 IDSA minor criteria (RR 28 close to threshold, multilobar). The ED team planned floor admission.

On a clinical admission consult the treating clinicians obtained a point-of-care lactate which returned 4.8 mmol/L. They escalated triage to ICU directly, drew blood cultures × 2 + sputum at the same time as IV access placement, and started ceftriaxone 2 g IV + azithromycin 500 mg IV (both delivered within 45 minutes of ED arrival). He had recent hospitalization 6 weeks prior so the treating clinicians added vancomycin for MRSA coverage. Within 4 hours of ICU arrival he required HFNC at 50 L/min and FiO2 0.6, and they added hydrocortisone 200 mg/day continuous infusion per CAPE COD protocol. Blood cultures returned MRSA at 36 hours. He never required intubation, defervesced at 72 hours, and was transitioned to floor at day 4 and discharged at day 8.

Takeaway: Lactate is the single most useful triage add-on for borderline-severe CAP. Combined with risk-stratified MRSA/Pseudomonas coverage and CAPE COD hydrocortisone for HFNC-or-greater respiratory support, the hour-1 admission package determines the outcome trajectory more than any later intervention.

Practice Pattern Refinements vs Standard Approach

  • Point-of-care lactate within 15 min for borderline severe (2 of 9 minor + clinician concern). Lactate ≥4 escalates to ICU regardless of formal count.
  • Hour-1 antibiotic + cultures simultaneous, not antibiotic-then-cultures. Standing orders: blood cx × 2 from separate sites at first IV access placement.
  • MRSA coverage if: prior MRSA isolate, cavitary infiltrate, post-influenza, ESRD HD, recent hospitalization/IV abx 90d. Pseudomonas coverage if: structural lung disease, recent hosp/IV abx 90d, prior Pseudomonas isolate.
  • Hydrocortisone 200 mg/day continuous infusion × 4 d then taper for severe CAP on HFNC/NIV/mech vent (CAPE COD 2023), separate from septic shock corticosteroid pathway.
Severe CAP: 4-Pillar Order Set Framework Four-panel framework: lactate triage, hour-1 antibiotic + culture, MRSA/Pseudomonas risk stratification, CAPE COD hydrocortisone. Severe CAP: 4-Pillar Admission Framework 1. Lactate Triages the Borderline For 2 of 9 minor + concern: < 2 mmol/L: floor / SDU OK 2-4: closer obs / SDU ≥ 4: ICU regardless of count POC lactate within 15 min triage Avoids floor-then-rapid-response trap 2. Hour-1 Antibiotic + Cultures 0 min 30 min 60 min Blood cx × 2 + sputum + IV First antibiotic dose Simultaneous, not sequential Culture sens drops after antibiotic Standing order at ED triage Both within 60 min of severe call 3. MRSA + PsA Risk-Stratified Add MRSA coverage if any: Prior MRSA isolate · cavitary infiltrate Post-influenza · ESRD HD · recent abx 90d Add PsA coverage if any: Structural lung disease · bronchiectasis Recent hosp / IV abx 90d · prior PsA Otherwise: CTX + azithromycin alone Avoid empiric vanc-cefepime overuse 4. CAPE COD Hydrocortisone (2023) Add if respiratory support is: HFNC at FiO2 > 50% Non-invasive ventilation Mechanical ventilation Hydrocortisone 200 mg/d × 4 d, taper Exclude: fungal, untreated TB, influenza Separate from septic shock corticosteroid
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *